Laiping Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laiping Zhong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Liqiong Xue
Shanghai East Hospital 1 Department of Oncology School of Medicine, Tongji University, Shanghai, China
4 shared publications - Meiyu Fang
Department of Head and Neck and Rare Oncology, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, China
4 shared publications - Qingyuan Zhang
Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin Medical University Harbin China
4 shared publications - Si-Yang Wang
Fifth Affiliated Hospital of Sun Yat-sen University 3
4 shared publications - Songnan Zhang
Yanbian University Hospital Yanji China
4 shared publications - Xia Li
Liaoning Cancer Hospital & Institute 4 Department of Radiotherapy and Chemotherapy Shenyang, China
4 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose:This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options.Patients and Methods:Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR).Results:Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%).Conclusions:Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose:This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options.Patients and Methods:Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR).Results:Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%).Conclusions:Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Supplementary Methods, Supplementary Tables S1-6, Supplementary Figure S1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Supplementary Methods, Supplementary Tables S1-6, Supplementary Figure S1
- 28 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1445-1453
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose: This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options. Patients and Methods: Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR). Results: Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%). Conclusions: Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- 28 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1445-1453
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose: This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options. Patients and Methods: Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR). Results: Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%). Conclusions: Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).